Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21325431 | 0.83 | DRD4 (0.34) | — | |
| SCHEMBL12384784 | 0.74 | OPRD1 (0.31) | NEK2 | |
| SCHEMBL23419794 | 0.74 | GRIN2D (0.43) | — | |
| SCHEMBL18531894 | 0.73 | — | — | |
| SCHEMBL16451672 | 0.72 | DRD4 (0.30) | — | |
| SCHEMBL19962291 | 0.72 | — | — | |
| SCHEMBL1091447 | 0.72 | OPRM1 (0.44) | — | |
| SCHEMBL9910019 | 0.69 | — | — | |
| SCHEMBL23345009 | 0.69 | GAA (0.32) | — | |
| SCHEMBL13262645 | 0.69 | CHRM2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | THE GENERAL HOSPITAL CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11136615-B2 | Compositions and methods for stabilizing benzothiazole luciferin analogs | PROMEGA CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20190040449-A1 | COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-02-07 | — | — | US | disclosed |
| US-20080027118-A1 | Prodrugs Of Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-7304063-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7301028-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070244055-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-10-18 | — | — | US | disclosed |
| US-7273869-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BRADY STEPHEN F | 2007-06-07 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | NEK2 1032/4885 |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | NEK2 1081/4885 |
| US-20080027118-A1 | Prodrugs Of Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF23 | NEK2 244/4885 |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | NEK2 1081/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | NEK2 199/4885 |
| US-20190040449-A1 | COMPOSITIONS AND METHODS FOR STABILIZING BENZOTHIAZOLE LUCIFERIN ANALOGS | TK1, TYMP, NUDT1 | NEK2 683/4885 |
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | NEK2 2729/4885 |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | NEK2 1081/4885 |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | NEK2 588/4885 |
| US-20070129309-A1 | Conjugates useful in the treatment of prostate cancer | BPHL, KLK3, DNPEP | NEK2 3397/4885 |
| US-20070082906-A1 | Inhibitors of akt activity | AKT2, AKT1, AKT3 | NEK2 131/4885 |
| US-11136615-B2 | Compositions and methods for stabilizing benzothiazole luciferin analogs | TK1, TYMP, NUDT1 | NEK2 683/4885 |
| US-20070244055-A1 | Conjugates useful in the treatment of prostate cancer | BPHL, KLK3, DNPEP | NEK2 3688/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | NEK2 178/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | NEK2 1032/4885 |
| US-20220133916-A1 | HDAC6 Inhibitors and Imaging Agents | HDAC1, HDAC6, HDAC11 | NEK2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.